US FDA clears new Merck drug for hepatitis C

Merck & Co won US approval on Friday to sell a new drug considered a major advance against the liver-destroying hepatitis C virus.
Victrelis is expected to help transform treatment of the potentially fatal disease with higher cure rates and shorter courses of therapy for some patients.